Zymeworks updates 2026 outlook after Theravance Biopharma deal, sees revenue $278–$292 million and adjusted EBITDA $114–$128 million
https://finviz.com/stock?t=ZYME&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.